Gabapentin is an Efficacy Treatment for Facial Flushing and Erythema of Erythematotelangiectatic Rosacea: A Randomized Clinical noninferiority Trial

Published: 13 December 2024| Version 1 | DOI: 10.17632/8prrf8pgpj.1
Contributors:
Jinyu Wei, Jian Li, Mei Wan, Qiquan Chen, Jian Fu, Ling Yang, Rongrong Ni, Lan Ge, Yanjun Dan, Xiao Chen, Minmin Kong, Ling Li, Shuguang Chen, Shichao Yang, Lian Zhang, Aiai Xia, Li Tang, Yanqi Zhang, Mingwang Zhang, Zhiqiang Song

Description

In this dataset, we have provided supplementary information for the study titled "Gabapentin is an Efficacy Treatment for Facial Flushing and Erythema of Erythematotelangiectatic Rosacea: A Randomized Clinical Noninferiority Trial." The supplementary materials include supplementary Figures and tables. A detailed description is provided below: Supplementary Figure 1. Study flow diagram. Supplementary Figure 2. The correlations between PSOI and VAS score improvement with CEA improvement in the gabapentin and carvedilol group at 12 weeks. The improvement in PSQI score (A) and VAS score for migraine (B) during gabapentin treatment was associated with the improvement in the CEA scores at 12 weeks. The improvement in PSQI score (C) and VAS score for migraine (D) during carvedilol treatment was no correlation with the improvement in the CEA scores at 12 weeks. Supplementary Table 1. Baseline of demographic and clinical characteristics in patients with ETR. Supplementary Table 2. Outcomes of anxiety and depression in gabapentin and carvedilol treatment. Supplementary Table 3. Overview of TEAEs in the safety population Supplementary Table 4. Clinician’s Erythema Assessment (CEA) scale Supplementary Table 5. Patient’s Self-Assessment (PSA) scale

Files

Categories

Sleep Disorder, Migraine, Rosacea, Emerging Treatment

Licence